Zedenoleucel · MT-401

What is Zedenoleucel?

Zedenoleucel (MT-401) is an off-the-shelf allogeneic T cell therapy composed of donor-derived T lymphocytes engineered to recognize four tumor-associated antigens: WT1, PRAME, NY-ESO-1, and survivin. Upon infusion, the cells recognize and kill cancer cells expressing these antigens. It is studied in acute myeloid leukemia, myelodysplastic syndrome, and post-stem cell transplantation settings.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

MT-401

Drug type

Cell therapy

Targets

WT1 (antigen), PRAME (antigen), NY-ESO-1 (CTAG1B) (antigen), survivin (BIRC5) (antigen)

Mechanism

Kills target cells, directed at WT1, PRAME and NY-ESO-1 (CTAG1B)

Therapy area

Oncology

Developer

Marker Therapeutics, Inc. (MRKR)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2

UNII

L4D9X59F34

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia, in RelapseMDSAcute Myeloid LeukemiaStem Cell Transplantation

More from Marker Therapeutics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT04511130
• ClinicalTrials.gov NCT06552416

Updated Oct 3, 2026.